KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Liabilities: 2020-2024

Historic Total Liabilities for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $413.8 million.

  • Recursion Pharmaceuticals' Total Liabilities rose 74.60% to $352.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $352.6 million, marking a year-over-year increase of 74.60%. This contributed to the annual value of $413.8 million for FY2024, which is 117.50% up from last year.
  • According to the latest figures from FY2024, Recursion Pharmaceuticals' Total Liabilities is $413.8 million, which was up 117.50% from $190.3 million recorded in FY2023.
  • Recursion Pharmaceuticals' Total Liabilities' 5-year high stood at $413.8 million during FY2024, with a 5-year trough of $56.6 million in FY2020.
  • For the 3-year period, Recursion Pharmaceuticals' Total Liabilities averaged around $273.2 million, with its median value being $215.5 million (2022).
  • In the last 5 years, Recursion Pharmaceuticals' Total Liabilities surged by 219.67% in 2022 and then fell by 11.70% in 2023.
  • Recursion Pharmaceuticals' Total Liabilities (Yearly) stood at $56.6 million in 2020, then increased by 19.17% to $67.4 million in 2021, then surged by 219.67% to $215.5 million in 2022, then dropped by 11.70% to $190.3 million in 2023, then surged by 117.50% to $413.8 million in 2024.